Abstract
Objectives We investigated the participation and detection rates of cervical lesions in cervical screening non-attenders offered HPV (human papillomavirus) self-sampling with cytology triage.Methods From 2016 to 2018, HPV self-sampling was routinely offered as an option, along with cytology, to all non-attenders in Ebetsu City, Japan. The primary endpoints were ≥CIN2 and ≥CIN3 detection rates, and secondary endpoints were abnormal cytology rates and follow-up compliance.Results Overall, recall invitations were mailed to 6,116 non-attenders, with a response rate of 15.9% (cytology: 6.5%, HPV testing: 9.4%). Of the responders to undergo HPV self-sampling, 11.7% had a positive result and were referred to cytology triage. Moreover, ≥CIN2 and ≥CIN3 detection rates were 1.7% and 0.9%, respectively, in the HPV self-sampling group, and 1.0% and 0.8%, respectively, in the cytology group, showing no statistically significant differences. In those who underwent cytology triage following an HPV positive test, ≥CIN2 and ≥CIN3 detection rates were 23.8% and 11.9%, respectively, which was significantly higher than those who only underwent cytology alone.Conclusion HPV self-sampling followed by cytology triage is highly effective at detecting high grade disease in non-attenders. Thus, multi-municipality-based studies to standardize processes involving this method are warranted. Furthermore, HPV self-sampling could be a promising method for inviting non-attenders who have difficulty undergoing cervical screening in the COVID-19 pandemic era.
Translated title of the contribution | Effect of choosing between cytological examination and self-collecting human papillomavirus test: results of measures for those who have not undergone cervical cancer screening in Hokkaido |
---|---|
Original language | Other |
Pages (from-to) | 719-727 |
Number of pages | 9 |
Journal | Nihon Koshu Eisei Zasshi |
Volume | 68 |
Issue number | 11 |
Early online date | 8 Jun 2021 |
DOIs | |
Publication status | Published - 15 Nov 2021 |
Keywords
- Female
- Humans
- *COVID-19
- SARS-CoV-2
- Early Detection of Cancer
- Mass Screening
- *Papillomavirus Infections/diagnosis
- *Uterine Cervical Neoplasms/diagnosis
- Triage
- *Uterine Cervical Dysplasia/diagnosis
- cervical screening
- Feasibility Studies
- feasibility study
- HPV test
- non-attender
- Pandemics
- recall
- self-sampling